NCT02529449View on ClinicalTrials.gov

Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 1, 2015

Primary Completion Date

March 19, 2016

Study Completion Date

March 19, 2016

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Placebo

Oral

DRUG

ASP1941

Oral

Trial Locations (11)

Unknown

Site JP00006, Aichi

Site JP00002, Fukuoka

Site JP00009, Gunma

Site JP00001, Ibaraki

Site JP00005, Kanagawa

Site JP00008, Kanagawa

Site JP00003, Okayama

Site JP00004, Osaka

Site JP00010, Osaka

Site JP00011, Osaka

Site JP00007, Tokyo

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT02529449 - Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter